Conexeu Sciences Inc. (CNXU) has registered 9,481,123 shares of common stock under an existing Form S-1 and is updating its prospectus with results for the quarter ended July 31, 2026.
The company, which has no commercial revenue and is developing its CXU™ regenerative skin therapy, reported a quarterly net loss of $7.7 million and a nine‑month net loss of $11.7 million, sharply higher than the prior year. Operating expenses reached $7.7 million for the quarter, driven mainly by consulting, business development, and related‑party management compensation. Cash and cash equivalents were $1.97 million (total cash and restricted cash $2.21 million) against $1.27 million in current liabilities, and management states that there is substantial doubt about the company’s ability to continue as a going concern without additional financing. Shares outstanding rose to 27.4 million at July 31, 2026 and 28.2 million by September 10, 2026, reflecting private placements, warrant inducement exercises, and share‑based payments.
Conexeu Sciences Inc. (CNXU), a pre‑revenue regenerative medicine company focused on its CXU device candidate, reported significantly higher losses for the quarter and nine months ended July 31, 2026 and disclosed that recent results raise substantial doubt about its ability to continue as a going concern without additional financing.
For the nine months, the company recorded a net loss of $11.7 million versus $2.0 million a year earlier, driven mainly by sharp increases in consulting, business development, regulatory, and management compensation expenses, including large share‑based payments. Net cash used in operating activities was $10.1 million, compared with $1.2 million in the prior‑year period.
As of July 31, 2026, Conexeu had cash and cash equivalents of $1.97 million and restricted cash of $0.24 million, total assets of $7.2 million, liabilities of $1.3 million, and shareholders’ equity of $5.9 million with an accumulated deficit of $16.3 million. The company strengthened its capital base through multiple private placements and warrant exercises and began trading on Nasdaq under the symbol CNXU on May 21, 2026, but it states that its business depends entirely on obtaining regulatory authorization and successfully commercializing CXU while securing further funding.
Conexeu Sciences Inc. (CNXU) files a prospectus supplement covering 9,481,123 shares of common stock under its Form S-1 and incorporates a new current report. The update discloses that from June 18, 2026 through September 4, 2026, the company issued 1,448,368 unregistered shares of common stock and 202,500 unregistered common stock purchase warrants, exceeding 5% of its outstanding shares since its last periodic report.
The largest single transaction was on September 4, 2026, when 762,608 shares were issued upon warrant exercises at $2.30 per share for $1,753,998.40 in gross proceeds, intended for working capital and general corporate purposes. Additional smaller issuances compensated consultants and directors and included June 18, 2026 warrant-related issuances generating approximately $162,202.50 plus a 250,000-share exercise at $0.001 per share. CNXU’s shares trade on the Nasdaq Capital Market at $4.25 per share as of September 10, 2026.
Conexeu Sciences Inc. (CNXU) reported a series of unregistered equity issuances from June 18, 2026 through September 4, 2026 that in aggregate exceeded 5% of its outstanding common stock, triggering disclosure under Item 3.02. Over this period, the company issued 1,448,368 unregistered shares of common stock and 202,500 unregistered common stock purchase warrants under various consulting, marketing, director, and warrant exercise arrangements.
The largest single transaction occurred on September 4, 2026, when Conexeu issued 762,608 shares upon warrant exercises at $2.30 per share for $1,753,998.40 in gross proceeds, which it intends to use for working capital and general corporate purposes. Additional issuances included cashless and low‑priced warrant exercises and share grants to consultants and directors at deemed prices between $0.001 and $13.96 per share. All securities were issued as "restricted securities" in reliance on private offering exemptions, primarily Rule 506(b) of Regulation D, Section 4(a)(2), and Rule 903(b) of Regulation S.
Conexeu Sciences Inc. (CNXU) insider Lynn Sebastian Purcell, through OnePointTwo Capital Ventures LLC, exercised warrants to acquire 217,608 shares of common stock at $2.30 per share on September 4, 2026. The amendment clarifies that the same 217,608 warrants were disposed of upon exercise, correcting a prior coding error. After the transaction, entities managed by OnePointTwo Capital Management LLC hold 2,951,848 shares of common stock and 407,392 warrants indirectly attributable to Purcell, who may be deemed a beneficial owner but disclaims beneficial ownership beyond any pecuniary interest. No Rule 10b5-1 trading plan is reported.
Conexeu Sciences Inc. (CNXU) reported that director and ten percent owner Lynn Sebastian Purcell, through OnePointTwo Capital Ventures LLC, exercised warrants to acquire 217,608 shares of common stock on September 4, 2026 at an exercise price of $2.30 per share. Following the exercise, entities managed by OnePointTwo Capital Management LLC held 2,951,848 shares of common stock and 407,392 warrants, all reported as indirect holdings over which Purcell has voting and investment power but for which he disclaims beneficial ownership except to the extent of his pecuniary interest. No Rule 10b5-1 trading plan is reported.
Conexeu Sciences Inc. (CNXU) received an amended Schedule 13G showing that Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund reports beneficial ownership of 4,314,336 common shares, representing up to 9.99% of the company’s common shares as of June 30, 2026.
The reported position includes 2,200,000 common share warrants, which may not be exercised if doing so would cause the holder to exceed 9.99% of Conexeu Sciences Inc.’s outstanding common shares on the exercise date. The reporting person has sole voting and dispositive power over the reported securities.
Conexeu Sciences Inc. (CNXU) has a significant shareholder reported on a Schedule 13G. Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund is disclosed as beneficially owning 4,400,305 common shares, including 2,200,000 common share warrants. The filing states this represents ownership of up to 9.99% of the outstanding common shares. The fund reports sole voting and dispositive power over all of these securities, subject to a 9.99% beneficial ownership limitation that restricts warrant exercises above that level.
Conexeu Sciences Inc. (CNXU), a Nevada biotechnology corporation, filed a Form D for a new exempt offering of equity securities under Rule 506(b) of Regulation D. The first sale occurred on 2026-08-24.
The filing reports equity issued as payment for consulting services with an aggregate offering amount of $88,548, consisting of 6,500 shares at $8.89 per share, 3,658 shares at $2.30 per share, and 1,601 shares at $13.96 per share. The total amount sold is $88,548 with $0 remaining to be sold, and reported finders' fees are $0.
Conexeu Sciences Inc. director Jeffrey Sharpe reports beneficial ownership of 1,500,000 shares of common stock of CNXU, representing 5.4% of the class. This includes 1,000,000 shares held directly and 500,000 shares issuable upon exercise of vested performance warrants that are currently exercisable.
Sharpe originally received 2,000,000 Performance Warrants at an exercise price of $0.001 per share under a May 14, 2025 consulting agreement, vesting in four 500,000-warrant tranches tied to specific milestones, including a collagen study, Nasdaq listing, sustained $80,000,000 market capitalization, and an FDA 510(k) application. He exercised 500,000 vested warrants in December 2025 and another 500,000 in May 2026, each time paying aggregate consideration of $500.00. An additional 500,000 warrants vested on June 18, 2026 based on the market capitalization milestone and remain unexercised, while the final 500,000 warrants will vest only upon submission of a 510(k) application.